Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Research Subsidiary of Eisai to Move to Kobe Strategic Zone
July 31, 2012
- Major Domestic Makers’ Vaccine Business Gains Momentum; Addition of New Vaccines to Public Vaccination Program Could Spark Debate Over Funding
July 31, 2012
- Afatinib Significantly Improves PFS in Japanese NSCLC Patients: BI Japan
July 31, 2012
- Kyowa Kirin Launches Apokyn for Parkinson’s Disease
July 31, 2012
- Sanofi-aventis Reaches Settlement with Sawai, Takata Seiyaku in Allegra Patent Dispute; Allegra’s Use Patent Validity Established
July 31, 2012
- Takeda Resubmits NDAs to US FDA for Alogliptin
July 31, 2012
- DPP-4 Inhibitor “Indispensable” to Strengthen Priority Field: Kyowa Kirin
July 30, 2012
- Kyowa Kirin’s 1st Half Pharmaceuticals Business Log 9.2% Sales Rise, but Operating Profits Fall
July 30, 2012
- US FDA Withholds Approval for Injectafer Due to Manufacturing Facility Issues: Daiichi Sankyo
July 30, 2012
- Approval for Once-Monthly Aripiprazole Hits Snag in US: Otsuka
July 30, 2012
- DSP, Nitto Denko Initiate PII Studies for Transdermal Patch Lonasen
July 30, 2012
- Eisai Receives Approval in Europe for Antiepileptic Perampanel; Launch in September
July 30, 2012
- Market Exclusivity for Lunesta Extended 6 Months in the US: DSP
July 30, 2012
- Celgene Initiates PII Trial in Japan for Revlimid in Treatment-Naïve Patients with Multiple Myeloma
July 30, 2012
- Pfizer Japan Files NDA for Prevnar 13 for Infant Use
July 30, 2012
- Kobayashi Kako Completes Construction of Anticancer Drug Manufacturing Facility
July 30, 2012
- Alfresa Launches Advanced Temperature-controlled Distribution Service
July 30, 2012
- Chugai’s 1st-Half Sales Excluding Tamiflu Down 0.3% in Japan as Mircera Slumps
July 30, 2012
- Chugai Had Tough Start in Final Year of Midterm Plan: Chairman Nagayama
July 30, 2012
- Takeda Initiates PIII Trial for Anticancer Agent Motesanib in Asia
July 27, 2012
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…